Many factors make genetically complex diseases complex. Classically they are defined as an interaction between multiple genetic variants and non-genetic factors. Progress in genome sequencing and within-species variation has generated much interest in identifying polygenic variants from human and model organisms, with some success. But one cannot lose sight of the importance of physiological complexity; even Mendelian variants can wreak havoc when operating in a complex biological system. For functional phenotypes, such as excitability disorders of the CNS, this concept is understudied. Epilepsy is genetically complex to be sure, but as the canonical excitability disorder of the brain it also serves as a leading example for approaching other, harder-to-crack functional disorders, such as autism and schizophrenia, that are also likely to have excito-pathology at their cores. Neuronal excitability is determined primarily by molecules, such as ion channels and transporters, neurotransmitter receptors, and synaptic proteins, controlling membrane potential and synaptic signaling in order to achieve an appropriate balance of excitation and inhibition. Although cis-variants in genes encoding these molecules can lead to specific phenotypes, trans-factors that regulate their expression must be critical for maintaining this balance at a higher, coordinated level. We previously identified and characterized hypomorphic and null genotypes in Celf4 (formerly known as Brunol4), encoding a brain-specific member of the BRUNO/CUGBP/CELF family of RNA binding proteins. Celf4 mutants have a complex seizure disorder and other neurological phenotypes, such as hyperactivity, mild obesity and abnormal social interaction. Very recently human CELF4 deficiency revealed these and additional symptoms, such as intellectual disability. In our initial funding period, we found that CELF4 is most tightly associated with very high-density RNA granule particles and targets a vast number of mRNAs in excitatory neurons. Many targets are involved in synaptic functions, and they tend to be dysregulated within neurons of mutant mice - in all directions, but with a tendency towards increased expression away from the cell body. These findings are consistent with a role for CELF4 in control translational silencing perhaps at local, subcellular levels. We also obtained evidence for CELF4 effects on intrinsic neuronal hyperexcitation, via increased expression of sodium channel Nav1.6, and system-wide dysregulation via impaired homeostatic plasticity presumably due to dysregulation of synaptic proteins. Our hypothesis is that the combination of such effects accounts for full-blown disease. In the next 5 years, our research will address two prevailing themes that work together to address this idea. The first addresses the pattern of CELF4 binding motifs within the 3'-UTR of target mRNAs, and the consequences of altering the motifs on mRNA abundance, localization and translation, both transcriptome-wide and for selected targets. The second theme uses in vivo mutagenesis to assess the contribution of individual targets to the multigenic etiology of complex neurological phenotypes.

Public Health Relevance

Epilepsy, autism, intellectual disability and psychiatric disorders, such as schizophrenia, are devastating but often non-degenerative brain diseases with overlapping causes, generally involving a failure of neurons to inter-communicate or to respond to normal regulatory cues. Our proposal considers the brain-specific RNA binding protein CELF4. CELF4 deficient patients and mice have similar neurological profiles, including seizures, hyperactivity and social disabilities; patients also have learning problems not yet examined in mice. However, CELF4 directly regulates the expression of hundreds of messenger RNAs, including many that are already known to be important for neuron development and regulation or cause genetic brain diseases in their own right. Our efforts, focused on understanding how CELF4 regulates its target genes in the brain, are likely to have broad implications for this group of inter-connected brain disorders.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS091118-05
Application #
9624824
Study Section
Genetics of Health and Disease Study Section (GHD)
Program Officer
Mamounas, Laura
Project Start
2015-02-01
Project End
2020-01-31
Budget Start
2019-02-01
Budget End
2020-01-31
Support Year
5
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Columbia University (N.Y.)
Department
Genetics
Type
Schools of Medicine
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032